Does Dr. HOSSEIN ALIMADADIAN have financial conflicts of interest?

Dr. HOSSEIN ALIMADADIAN (M.D.) has received a total of $3,646 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $3,646 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. HOSSEIN ALIMADADIAN?

According to CMS Open Payments data, Dr. HOSSEIN ALIMADADIAN received funding from NOVARTIS PHARMACEUTICALS CORPORATION ($652), BOEHRINGER INGELHEIM PHARMACEUTICALS ($369), and ASTRAZENECA PHARMACEUTICALS ($268).

Does Dr. HOSSEIN ALIMADADIAN receive research grants or speaking fees?

Dr. HOSSEIN ALIMADADIAN has received $3,646 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. HOSSEIN ALIMADADIAN

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Cardiovascular Disease

Practice Location: ORANGE, CA 92868

NPI Number: 1285664029

LIFETIME INDUSTRY VALUE

$3,646

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ALIMADADIAN is a verified Internal Medicine, Cardiovascular Disease practitioner based in ORANGE, CA.

Between 2021 and 2024, Dr. ALIMADADIAN had an overall industry promotional and research financial footprint of $3,646 as recorded in the federal CMS Open Payments database.

$3,646 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ALIMADADIAN's primary funding source is NOVARTIS PHARMACEUTICALS CORPORATION, which accounts for $652 (representing 17.9% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 1

$652

17.9%

BOEHRINGER INGELHEIM PHARMACEUTICALS

Rank 2

$369

10.1%

ASTRAZENECA PHARMACEUTICALS

Rank 3

$268

7.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.